1,134 results match your criteria American Journal of Clinical Dermatology[Journal]


Autoinflammatory Disorders: A Review and Update on Pathogenesis and Treatment.

Am J Clin Dermatol 2019 Apr 17. Epub 2019 Apr 17.

Icahn School of Medicine at Mount Sinai, New York, NY, USA.

The autoinflammatory diseases comprise a broad spectrum of disorders characterized by unchecked activation of the innate immune system. Whereas aberrations in adaptive immunity have long been identified in 'autoimmune' disorders, the concept of 'autoinflammation' emerged relatively recently, first describing a group of clinical disorders characterized by spontaneous episodes of systemic inflammation without manifestations typical of autoimmune disorders. Improved knowledge of innate immune mechanisms, coupled with remarkable progress in genomics and an expanding number of clinical cases, has since led to an increasing number of disorders classified as autoinflammatory or containing an autoinflammatory component. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-019-00440-y
Publisher Site
http://dx.doi.org/10.1007/s40257-019-00440-yDOI Listing
April 2019
4 Reads

Special Considerations in the Treatment of Mycosis Fungoides.

Am J Clin Dermatol 2019 Apr 16. Epub 2019 Apr 16.

Department of Dermatology and Cutaneous Biology, Sidney Kimmel College at Jefferson University Hospital, Thomas Jefferson University, 833 Chestnut Street, Suite 740, Philadelphia, PA, 19107, USA.

Mycosis fungoides is the most common form of cutaneous T cell lymphoma. Although normally presenting to physicians at an early stage and with an indolent course, mycosis fungoides can have a varied presentation. The National Comprehensive Cancer Network (NCCN) has created guidelines for the treatment and staging of mycosis fungoides. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00431-zDOI Listing
April 2019
8 Reads

Vascular Tests for Dermatologists.

Am J Clin Dermatol 2019 Apr 15. Epub 2019 Apr 15.

Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.

Dermatologists encounter patients with a variety of lower extremity ulcers including those related to venous insufficiency and peripheral arterial disease. Vascular studies, including ankle brachial pressure index, toe pressure, toe brachial index, Doppler arterial waveform, Duplex ultrasonography, and angiography, play an essential role in the prevention, diagnosis, and management of vascular diseases. In fact, dermatologists are often the first medical providers to see patients with complex vascular conditions. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-019-00441-x
Publisher Site
http://dx.doi.org/10.1007/s40257-019-00441-xDOI Listing
April 2019
2 Reads

Quality-of-Life Research in Acne Vulgaris: Current Status and Future Directions.

Am J Clin Dermatol 2019 Apr 4. Epub 2019 Apr 4.

Department of Psychology, University of Zaragoza, C/Pedro Cerbuna 12, 50009, Saragossa, Spain.

Acne patients may have significant quality-of-life (QoL) impairment, therefore assessment of health-related QoL (HRQoL) in acne patients is recommended by several national and international guidelines as an integral part of acne management. The inclusion of QoL assessment in core outcome sets is now a popular idea. Several acne-specific QoL questionnaires are available but none cover all topics presented in other instruments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00438-6DOI Listing
April 2019
1 Read

Effect of Biological Treatment on Fatigue in Psoriasis: A Systematic Review and Meta-Analysis.

Am J Clin Dermatol 2019 Apr 2. Epub 2019 Apr 2.

Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, PO Box 8100, 4068, Stavanger, Norway.

Background: Fatigue is frequent in patients with psoriasis. Though conventional drugs in general have no effect on fatigue, biological agents have demonstrated beneficial effects in several other chronic inflammatory diseases.

Objective: The objective of the present study was to evaluate the effect of biological drugs on fatigue in patients with psoriasis vulgaris. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00434-wDOI Listing
April 2019
3 Reads

Psychological Therapies in Management of Psoriatic Skin Disease: A Systematic Review.

Am J Clin Dermatol 2019 Apr 2. Epub 2019 Apr 2.

George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

Background: Psoriasis is a chronic, immune-mediated skin disease shown to have a multifaceted relationship with psychological factors. Because these factors have been shown to both worsen and result from psoriasis, an increasing number of studies have sought to investigate the efficacy of various psychological interventions in psoriasis management.

Methods: A systematic review of PubMed and Scopus databases was performed for studies investigating psychological interventions in psoriasis management published from 1 January 1990 through 4 November 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00437-7DOI Listing
April 2019
1 Read

Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis.

Authors:
James E Frampton

Am J Clin Dermatol 2019 Apr;20(2):295-306

Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Tildrakizumab (tildrakizumab-asmn in the USA) [Ilumetri; Ilumya™] is a humanized monoclonal antibody (mAb) that selectively targets the p19 subunit of interleukin (IL)-23, thereby inhibiting the IL-23/IL-17 axis, the signalling pathway primarily implicated in the immunopathogenesis of psoriasis. Administered subcutaneously, it is approved for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00435-9DOI Listing
April 2019
1 Read

Management Recommendations for Dupilumab Partial and Non-durable Responders in Atopic Dermatitis.

Am J Clin Dermatol 2019 Mar 27. Epub 2019 Mar 27.

Division of Dermatology, Department of Medicine, University of Arizona, 7165 N Pima Canyon Drive, Tucson, AZ, 85718, USA.

As the first targeted systemic agent for the treatment of moderate to severe atopic dermatitis (AD), dupilumab represents a novel therapeutic opportunity for both patients and providers. However, a subset of patients receiving dupilumab are either partial responders who exhibit some improvement in Investigator's Global Assessment score but not sufficient to meet the primary endpoint, or are non-durable responders who achieve therapeutic endpoint with subsequent partial loss of efficacy. We propose a therapeutic algorithm for the management of dupilumab partial responders and non-durable responders that involves maximizing topical therapy, seeking alternative diagnoses, and using dupilumab in conjunction with traditional systemic immunosuppressive agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00436-8DOI Listing

Active Tuberculosis in Patients with Psoriasis Receiving Biologic Therapy: A Systematic Review.

Am J Clin Dermatol 2019 Mar 27. Epub 2019 Mar 27.

Department of Dermatology, Rabin Medical Center, Beilinson Hospital, 39 Jabotinsky St, 4941492, Petah Tikva, Israel.

Background: Biologic therapies pose a risk for opportunistic infections, especially for reactivating latent tuberculosis infection (LTBI).

Objective: The aim was to describe the clinical features and mortality rate of active Mycobacterium tuberculosis (TB) in psoriasis patients receiving biologic therapies.

Methods: A systematic review of PubMed, Google Scholar, ScienceDirect, Cochrane Library, and ClinicalTrials. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-019-00432-y
Publisher Site
http://dx.doi.org/10.1007/s40257-019-00432-yDOI Listing
March 2019
1 Read

Childhood Vitiligo.

Am J Clin Dermatol 2019 Mar 25. Epub 2019 Mar 25.

First Department of Dermatology and Venereology, National and Kapodistrian University of Athens School of Medicine, "A. Sygros" Hospital for Skin and Venereal Diseases, Athens, Greece.

Vitiligo is a common acquired depigmenting skin disease characterized by a progressive loss of functional melanocytes. It may appear from the first years of life to late adulthood. Childhood vitiligo (CV), defined as vitiligo that begins before the age of 12 years, is common and may differ from post-CV in terms of epidemiology, clinical presentation, comorbidities, and treatment options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00430-0DOI Listing
March 2019
1 Read

Biologic Therapy in the Treatment of Cutaneous Sarcoidosis: A Literature Review.

Am J Clin Dermatol 2019 Mar 20. Epub 2019 Mar 20.

Department of Medicine, University of Central Florida College of Medicine, Health Sciences Campus at Lake Nona, 6850 Lake Nona Blvd, Orlando, FL, 32827-7408, USA.

Sarcoidosis is an inflammatory disease defined by the presence of non-caseating granulomas. It can affect a number of organ systems, most commonly the lungs, lymph nodes, and skin. Cutaneous manifestations of sarcoidosis can impose a significant detriment to patients' quality of life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00428-8DOI Listing
March 2019
1 Read

American Academy of Dermatology Annual Meeting: Washington, DC, USA, 1-5 March 2019.

Authors:
Kathy A Fraser

Am J Clin Dermatol 2019 Apr;20(2):307-310

Adis Publications, Auckland, New Zealand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00433-xDOI Listing

Chronic Cutaneous Lupus Erythematosus: Depression Burden and Associated Factors.

Am J Clin Dermatol 2019 Mar 15. Epub 2019 Mar 15.

Department of Medicine, Division of Rheumatology, Emory University, Atlanta, GA, USA.

Objectives: Depression may occur in up to 30% of individuals with cutaneous lupus erythematosus (CLE), many of whom may also have systemic manifestations. Chronic cutaneous lupus erythematosus (CCLE) conditions are less likely to present systemic involvement than acute and subacute conditions but more often cause permanent scarring and dyspigmentation. However, little is known about depression in those who have CCLE confined to the skin (primary CCLE). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00429-7DOI Listing
March 2019
1 Read

HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management.

Am J Clin Dermatol 2019 Feb 26. Epub 2019 Feb 26.

Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Bartlett Hall 6R, Boston, MA, 02114, USA.

Antiretroviral therapy (ART) has revolutionized the treatment and prognosis of people living with HIV (PLHIV). With increased survival and improved overall health, PLHIV are experiencing dermatologic issues both specific to HIV and common to the general population. In this new era of ART, it is crucial for dermatologists to have a strong understanding of the broad range of cutaneous disease and treatment options in this unique population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00422-0DOI Listing
February 2019
1 Read

Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.

Authors:
Mahtab Samimi

Am J Clin Dermatol 2019 Feb 19. Epub 2019 Feb 19.

Dermatology Department, University Hospital of Tours, Avenue de la République, 37170, Chambray-les-Tours, France.

Merkel cell carcinoma (MCC) is an aggressive skin cancer. Until 2017, patients with advanced disease were typically treated with conventional chemotherapies, with a median response duration of 3 months. Increased evidence of the role of the immune system in controlling this cancer has paved the way for immune-based therapies, with programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) inhibitors at the frontline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00427-9DOI Listing
February 2019
8 Reads

Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma.

Am J Clin Dermatol 2019 Feb 8. Epub 2019 Feb 8.

Department of Dermatology, Stanford University School of Medicine, 450 Broadway Street, Mail Code 5334, Redwood City, CA, 94063, USA.

Cutaneous squamous cell carcinoma (CSCC) is one of the most common human malignancies, and the incidence is increasing with time. High mutational loads, known infiltration with lymphocytes, and programmed death (PD)-ligand 1 (PD-L1) expression suggest that immune checkpoint inhibitors, such as PD-1 inhibitors, may show utility in treating CSCC, similar to response see in other solid tumor types. Recently, the robust responsiveness of CSCCs to the PD-1 inhibitor cemiplimab was revealed in the results of a combined phase I/II clinical trial, with an overall response rate of 50% and a durable response exceeding 6 months in 57% of responders. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-019-00426-w
Publisher Site
http://dx.doi.org/10.1007/s40257-019-00426-wDOI Listing
February 2019
18 Reads

KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development.

Am J Clin Dermatol 2019 Feb 1. Epub 2019 Feb 1.

Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center and the Herbert Irving Comprehensive Cancer Center, New York, NY, USA.

Metastatic melanoma is a heterogenous disease that has served as a model for the development of both targeted therapy and immunotherapy. KIT-mutated melanoma represents a rare subset, most commonly arising from acral, mucosal, and chronically sun-damaged skin. Additionally, KIT alterations are enriched in the triple wild-type subtype of cutaneous melanoma. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0414-1
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0414-1DOI Listing
February 2019
8 Reads

Trends in Utilization and Expenditure for Onychomycosis Treatments in the United States in 2013-2016.

Am J Clin Dermatol 2019 Apr;20(2):311-313

Department of Dermatology, Preventive Medicine and Medical Social Sciences, Feinberg School of Medicine, Northwestern University, 676 N. St. Clair St., Suite 1600/Dermatology, Chicago, IL, 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00425-xDOI Listing

Topical Retinoids in Acne Vulgaris: A Systematic Review.

Am J Clin Dermatol 2019 Jan 23. Epub 2019 Jan 23.

Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, 1 Medical Center Boulevard, Winston-Salem, NC, 27157-1071, USA.

Background: Topical retinoids are a first-line treatment for acne vulgaris.

Objective: This systematic review aims to evaluate the efficacy, safety, and tolerability of topical retinoids approved in the United States for the treatment of acne vulgaris.

Methods: A PubMed and Embase search was conducted using the search terms 'adapalene,' 'tretinoin,' 'tazarotene,' and 'acne vulgaris. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-019-00423-z
Publisher Site
http://dx.doi.org/10.1007/s40257-019-00423-zDOI Listing
January 2019
11 Reads

Frontal Fibrosing Alopecia: An Update on Pathogenesis, Diagnosis, and Treatment.

Am J Clin Dermatol 2019 Jan 19. Epub 2019 Jan 19.

Fredric Brandt Endowed Professor of Dermatology, Miller School of Medicine, University of Miami, Miami, FL, USA.

Frontal fibrosing alopecia (FFA), first described by Kossard in the early 1990s, is a form of primary lymphocytic cicatricial alopecia characterized by selective involvement of the frontotemporal hairline and eyebrows. Since the original description, an increasing number of cases have been reported worldwide and the clinical aspects of the disease have been better characterized. However, the pathogenesis is still unknown and several hypotheses have been made about possible triggering factors, including hormones, neurogenic inflammation, smoking, UV filters, and ingredients in leave-on facial products. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00424-yDOI Listing
January 2019
7 Reads

Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS): How Far Have We Come?

Am J Clin Dermatol 2019 Apr;20(2):217-236

Department of Dermatology, University of Toronto, Toronto, Canada.

Drug reaction with eosinophilia and systemic symptoms (DReSS), also known as drug-induced hypersensitivity syndrome (DiHS), is an uncommon severe adverse reaction to medications. It is important to recognize it as it is potentially fatal and can cause significant morbidity. From the first reports of drug reactions related to certain anticonvulsants characterized by fever, liver enzyme elevation, and skin changes, our continuously growing understanding of this entity has allowed us to describe its physiopathology and clinical features even further. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-018-00416-4DOI Listing
April 2019
2 Reads

Association Between Psoriasis and Dementia: A Population-Based Case-Control Study.

Am J Clin Dermatol 2019 Jan 16. Epub 2019 Jan 16.

Graduate Institute of Biomedical Informatics, College of Medicine Science and Technology, Taipei Medical University, 250 Wu-Hsing St., Taipei, 110, Taiwan.

Background: Dementia is a syndrome that involves the deterioration of several higher mental functions in advanced age, and psoriasis is an autoimmune disease characterized by skin plaque. Epidemiological studies have indicated an association between dementia and psoriasis; however, to date, no studies in Asia have reported this association.

Objective: This study used a population-based medical dataset to explore the association between previously diagnosed psoriasis and dementia in Taiwan. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-00420-8
Publisher Site
http://dx.doi.org/10.1007/s40257-018-00420-8DOI Listing
January 2019
18 Reads

Acne, the Skin Microbiome, and Antibiotic Treatment.

Am J Clin Dermatol 2019 Jan 10. Epub 2019 Jan 10.

Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, 4339 CNSI, 570 Westwood Plaza, Building 114, Los Angeles, CA, 90095, USA.

Acne vulgaris is a chronic skin disorder involving hair follicles and sebaceous glands. Multiple factors contribute to the disease, including skin microbes. The skin microbiome in the follicle is composed of a diverse group of microorganisms. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-00417-3
Publisher Site
http://dx.doi.org/10.1007/s40257-018-00417-3DOI Listing
January 2019
12 Reads

Neutrophilic Dermatoses Associated with Myeloid Malignancies.

Am J Clin Dermatol 2019 Jan 10. Epub 2019 Jan 10.

Assistance Publique-Hôpitaux de Paris, Département de Pathologie, Hôpital Saint-Louis, Paris, France.

Neutrophilic dermatoses (ND) are a group of conditions characterized by an aseptic accumulation of polymorphonuclear leukocytes in the skin. Occurrence of ND in association with myeloid malignancies, mainly myelodysplastic syndrome and myelogenous acute leukemia, is not rare and is often associated with a poor prognosis. Recent findings have improved understanding of the pathophysiology of myeloid malignancy-associated ND. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-018-00418-2DOI Listing
January 2019
8 Reads

Correction to: JAK Inhibitors for Atopic Dermatitis: An Update.

Am J Clin Dermatol 2019 04;20(2):193

Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, 5 E. 98th Street, New York, NY, 10029, USA.

Page 7, Table 1, ASN002 row. The cell entry in column 4, "Manufacturer", which previously read. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00421-1DOI Listing
April 2019
1 Read

No Increased Risks Associated with Propranolol Treatment for Infantile Hemangioma in Preterm Infants were Identified at 3 Years of Age.

Am J Clin Dermatol 2019 Apr;20(2):289-293

Department of Dermatology, National Center for Children's Health, Beijing Children's Hospital, Capital Medical University, No. 56 Nanlishi Road, Beijing, 100045, China.

Background: Concerns have been raised that propranolol treatment of infantile hemangioma (IH) may be associated with increased risks of adverse effects and growth impairment in preterm infants due to their immature development.

Objective: This study aimed to find out whether treatment of IH with propranolol in preterm infants is associated with higher incidences of long-term adverse effects and growth impairment in comparison with term infants.

Methods: The clinical data of 55 preterm infants and 180 term infants with IH treated with oral propranolol for 6 months were retrospectively collected and analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-018-00419-1DOI Listing
April 2019
5 Reads
2.519 Impact Factor

Efficacy of Microneedling Versus Fractional Non-ablative Laser to Treat Striae Alba: A Randomized Study.

Am J Clin Dermatol 2019 Apr;20(2):277-287

Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.

Background: Striae distensae (SD), an unsightly cutaneous condition characterized by epidermal atrophy, can affect the quality of life of women.

Objectives: The aim of our study was to compare the efficacy of a neodymium:yttrium-aluminum-perovskite 1340 nm non-ablative fractional laser (NAFL) and the microneedling (MN) technique to treat striae alba (SA).

Materials And Methods: NAFL and MN were used to treat striae on the longitudinally divided abdominal surface of 20 women classified as Fitzpatrick skin type III or IV (five sessions at monthly intervals). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0415-0
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0415-0DOI Listing
April 2019
10 Reads

Off-Label Use of Topical Minoxidil in Alopecia: A Review.

Am J Clin Dermatol 2019 Apr;20(2):237-250

Department of Dermatology, Northwestern University, 676 N St Clair St, Suite 1600, Chicago, IL, 60611, USA.

Topical minoxidil is a well-known and often-utilized drug in dermatological practice for the treatment of alopecia. It was approved by the United States Food and Drug Administration for the treatment of androgenetic alopecia in 1988. Since its approval, minoxidil has been used off-label for the treatment of many other types of alopecia, with minimal formal evidence of efficacy. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0409-y
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0409-yDOI Listing
April 2019
10 Reads

Cannabinoids: Potential Role in Inflammatory and Neoplastic Skin Diseases.

Am J Clin Dermatol 2019 Apr;20(2):167-180

George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

The endocannabinoid system is a complex and nearly ubiquitous network of endogenous ligands, enzymes, and receptors that can also be stimulated by exogenous compounds such as those derived from the marijuana plant, Cannabis sativa. Recent data have shown that the endocannabinoid system is fully functional in the skin and is responsible for maintaining many aspects of skin homeostasis, such as proliferation, differentiation, and release of inflammatory mediators. Because of its role in regulating these key processes, the endocannabinoid system has been studied for its modulating effects on both inflammatory disorders of the skin and skin cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-018-0410-5DOI Listing
April 2019
1 Read

JAK Inhibitors for Atopic Dermatitis: An Update.

Am J Clin Dermatol 2019 Apr;20(2):181-192

Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, 5 E. 98th Street, New York, NY, 10029, USA.

Atopic dermatitis (AD) is one of the most common inflammatory skin diseases. AD is driven by barrier dysfunction and abnormal immune activation of T helper (Th) 2, Th22, and varying degrees of Th1 and Th17 among various subtypes. The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and spleen tyrosine kinase (SYK) pathways are involved in signaling of several AD-related cytokines, such as IFN-γ, IL-4, IL-13, IL-31, IL-33, IL-23, IL-22, and IL-17, mediating downstream inflammation and barrier alterations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-018-0413-2DOI Listing
April 2019
9 Reads

Alternative Treatments for Atopic Dermatitis: An Update.

Am J Clin Dermatol 2019 Apr;20(2):251-266

Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease in which management with topical anti-inflammatory agents during exacerbations remains the mainstay of treatment. With no cure in sight, a significant proportion of patients elect to incorporate complementary and alternative medicine (CAM) as an adjunct to conventional treatment. Many clinicians find it difficult to provide recommendations as the field covers an extensive number of very disparate therapies, with limited quality evidence to indicate efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-018-0412-3DOI Listing
April 2019
7 Reads

Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials.

Am J Clin Dermatol 2019 Apr;20(2):267-276

Mount Sinai St. Luke's and Mount Sinai West, New York, NY, USA.

Background: Data on treatment outcomes in patients with psoriasis who have skin of color are limited. Brodalumab has shown efficacy in patients with moderate-to-severe plaque psoriasis.

Objective: Our objective was to evaluate the efficacy, safety, and health-related quality of life associated with brodalumab in patients with skin of color participating in two phase III, multicenter, randomized, double-blind, placebo- and active comparator-controlled studies (AMAGINE-2/-3). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-018-0408-zDOI Listing
April 2019
14 Reads

Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.

Am J Clin Dermatol 2018 Dec;19(6):907-918

Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Guselkumab (Tremfya) is a human immunoglobulin G1 λ (IgG1λ) monoclonal antibody (mAb) that blocks the interleukin-23 (IL-23)-mediated signalling pathway and is the first in its class to be approved in adults with moderate to severe plaque psoriasis in several countries, including the USA and EU. In the VOYAGE trials, guselkumab was superior to placebo and to adalimumab at week 16 in terms of the proportion of patients achieving an Investigator Global Assessment (IGA) score of 0/1 and ≥ 90% improvement from baseline in Psoriasis Area and Severity index score (PASI 90 response), with benefits of guselkumab over adalimumab maintained at week 24. To date, the beneficial effects of guselkumab treatment in these trials were maintained for up to 2 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-018-0406-1DOI Listing
December 2018
24 Reads

Probiotic Supplementation for Prevention of Atopic Dermatitis in Infants and Children: A Systematic Review and Meta-analysis.

Am J Clin Dermatol 2018 Nov 21. Epub 2018 Nov 21.

Department of Gastroenterology, Yijishan Hospital of Wannan Medical College, Wuhu, 241001, Anhui, People's Republic of China.

Background: Probiotic supplementation in early life may be effective in preventing atopic dermatitis (AD); however, results regarding efficacy have been controversial.

Objective: The aim of our study was to investigate the effect of probiotic supplementation on the risk of AD.

Methods: We systematically searched PubMed, EBSCO, Embase and Web of Science databases up to 8 March 2018 for potentially relevant studies regarding probiotic supplementation and AD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-018-0404-3DOI Listing
November 2018
15 Reads

A Practical Guide to Curing Onychomycosis: How to Maximize Cure at the Patient, Organism, Treatment, and Environmental Level.

Am J Clin Dermatol 2019 Feb;20(1):123-133

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Onychomycosis is a fungal nail infection caused by dermatophytes, non-dermatophyte molds, and yeasts. Treatment of this infection can be difficult, with relapse likely to occur within 2.5 years of cure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-018-0403-4DOI Listing
February 2019
12 Reads

Antibody-Based Therapies for Cutaneous T-Cell Lymphoma.

Am J Clin Dermatol 2019 Feb;20(1):115-122

University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1452, Houston, TX, 77030-4009, USA.

Cutaneous T-cell lymphomas (CTCLs) are a group of non-Hodgkin's lymphomas that present in the skin. In early-stage disease, the course is generally chronic and indolent; however, in advanced stages of disease, therapies rarely provide long-lasting responses, and the only potential curative therapy is allogeneic hematopoietic stem-cell transplantation. This has led to the search for novel targeted therapies to better treat more advanced stages of CTCLs that cannot be controlled by typical treatment regimens. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0402-5
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0402-5DOI Listing
February 2019
17 Reads

Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature.

Am J Clin Dermatol 2019 Apr;20(2):209-216

Department of Dermatology, Beilinson Hospital, Rabin Medical Center, Petah-Tikva, 49100, Israel.

Background: Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease worldwide. Systemic corticosteroids are considered the mainstay of therapy; however, they may cause significant adverse effects and treatment failures, so additional therapeutic modalities with better safety profiles are required. Rituximab and omalizumab are novel biologic agents administered in recent years for the treatment of BP, yet data regarding their use in the disease are limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-018-0401-6DOI Listing
April 2019
19 Reads

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.

Am J Clin Dermatol 2019 Feb;20(1):155-164

K Papp Clinical Research and Probity Medical Research Inc., Waterloo, ON, Canada.

Background: Health-related quality of life (HRQoL) may be markedly impaired in patients with moderate-to-severe psoriasis.

Objectives: Our objectives were to compare improvements in Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD) scores between patients receiving guselkumab compared with placebo or adalimumab and to correlate these improvements with skin clearance.

Methods: Pooled phase III VOYAGE 1 and VOYAGE 2 data were evaluated through week 24. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0396-z
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0396-zDOI Listing
February 2019
18 Reads
2.520 Impact Factor

Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled Trials.

Am J Clin Dermatol 2019 Feb;20(1):135-145

Saint Louis University, St. Louis, MO, USA.

Background: Glycopyrronium tosylate (GT) is a topical anticholinergic approved in the USA for primary axillary hyperhidrosis in patients aged ≥ 9 years. GT was evaluated for primary axillary hyperhidrosis in replicate, randomized, double-blind, vehicle-controlled, phase III trials. GT reduced sweating severity and production versus vehicle and was generally well tolerated. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0395-0
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0395-0DOI Listing
February 2019
22 Reads

Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.

Am J Clin Dermatol 2018 Nov;19(Suppl 1):31-39

Institut Universitaire du Cancer Toulouse - Oncopole, 1 avenue Irène Joliot-Curie, 31059, TOULOUSE Cedex 9, France.

Targeted therapies and immunotherapies are associated with a wide range of dermatologic adverse events (dAEs) resulting from common signaling pathways involved in malignant behavior and normal homeostatic functions of the epidermis and dermis. Dermatologic toxicities include damage to the skin, oral mucosa, hair, and nails. Acneiform rash is the most common dAE, observed in 25-85% of patients treated by epidermal growth factor receptor and mitogen-activated protein kinase kinase inhibitors. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0384-3
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0384-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244569PMC
November 2018
16 Reads

Homeostasis in Topical Photoprotection: Getting the Spectral Balance Right.

Authors:
Fernando Stengel

Am J Clin Dermatol 2018 Nov;19(Suppl 1):40-44

Buenos Aires Skin, Avenida Cordoba 1184, 10 Piso. (1055), Ciudad Autónoma de Buenos Aires, Argentina.

The solar radiation range has harmful and beneficial effects. Sunscreens, which selectively block specific spectral regions, may potentially interfere with skin homeostasis. For instance, the ultraviolet (UV) B waveband produces erythema and DNA damage; simultaneously, it induces pre-vitamin D synthesis. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0369-2
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0369-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244613PMC
November 2018
26 Reads

Noninvasive Imaging Tools in the Diagnosis and Treatment of Skin Cancers.

Am J Clin Dermatol 2018 Nov;19(Suppl 1):3-14

Hospital Provincial del Centenario de Rosario, Argentina, Diagnóstico Médico Oroño, Bv. Oroño 1515, 2000, Rosario, Argentina.

In the 1980s, the increasing incidence of skin cancers prompted the development of noninvasive medical devices to improve skin cancer diagnosis in daily dermatology practice. As a result of the development of these noninvasive techniques, diagnosis is now established earlier and with better accuracy. These advances are of great benefit to high-risk patients, who previously would have had to undergo several excisions. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0367-4
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0367-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244601PMC
November 2018
32 Reads

Unusual Clinical Presentations of Malignant Melanoma: A Review of Clinical and Histologic Features with Special Emphasis on Dermatoscopic Findings.

Am J Clin Dermatol 2018 Nov;19(Suppl 1):15-23

Department of Dermatology, Universidad del Desarrollo, Clínica Alemana, Manquehue Norte 1410, Vitacura, Santiago, Chile.

This review presents the main challenges encountered when diagnosing unusual variants of malignant melanoma with the aim of raising awareness to allow application of the most appropriate treatment strategies. Although these melanomas are often rare, their misdiagnosis potentially jeopardizes patients' health and survival, and has medicolegal implications. The clinical and histologic presentations of melanoma vary greatly, and assessment of uncommon melanomas can be difficult for practitioners because of their scarcity and resemblance to other dermatologic entities. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0373-6
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0373-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244635PMC
November 2018
16 Reads

Sentinel Lymph Node Biopsy: Past and Present Implications for the Management of Cutaneous Melanoma with Nodal Metastasis.

Authors:
Abel Gonzalez

Am J Clin Dermatol 2018 Nov;19(Suppl 1):24-30

Mohs Surgery Unit, Institute of Oncology Angel H. Roffo, University of Buenos Aires, Av San Martin 5481, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.

Although significant progress has been made in the understanding of melanoma pathophysiology and therapy, patients with metastatic melanoma still have a poor prognosis. The management of regional nodes remains a matter of debate. By replacing elective lymph node dissection, sentinel lymph node biopsy has revolutionized the treatment of malignant melanoma. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0379-0
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0379-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244615PMC
November 2018
7 Reads

Foreword.

Authors:
Fernando Stengel

Am J Clin Dermatol 2018 Nov;19(Suppl 1)

Buenos Aires Skin, Avenida Cordoba 1184, 10 Piso (1055), Buenos Aires, Argentina.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0392-3
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0392-3DOI Listing
November 2018
4 Reads

An Update on Drug-Induced Pigmentation.

Am J Clin Dermatol 2019 Feb;20(1):75-96

Department of Dermatology, Henry Ford Hospital, 3031 W. Grand Blvd., Suite 800, Detroit, MI, 48202, USA.

Drug-induced pigmentation accounts for up to 20% of all cases of acquired pigmentation. A thorough review of medical history and previous and ongoing medications as well as a complete skin examination can guide diagnosis. Implicated agents include alkylating/cytotoxic agents, analgesics, antiarrhythmics, anticoagulants, antiepileptics, antimalarials, antimicrobials, antiretrovirals, metals, prostaglandin analogs, and psychotropic agents, among others. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0393-2
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0393-2DOI Listing
February 2019
18 Reads

Monitoring Melanoma Using Circulating Free DNA.

Am J Clin Dermatol 2019 Feb;20(1):1-12

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, 2109, Australia.

Genetic material derived from tumours is constantly shed into the circulation of cancer patients both in the form of circulating free nucleic acids and within circulating cells or extracellular vesicles. Monitoring cancer-specific genomic alterations, particularly mutant allele frequencies, in circulating nucleic acids allows for a non-invasive liquid biopsy for detecting residual disease and response to therapy. The advent of molecular targeted treatments and immunotherapies with increasing effectiveness requires corresponding effective molecular biology methods for the detection of biomarkers such as circulating nucleic acid to monitor and ultimately personalise therapy. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0398-x
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0398-xDOI Listing
February 2019
15 Reads

Association of Multiple Sclerosis with Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.

Am J Clin Dermatol 2019 Apr;20(2):201-208

College of Medicine, Chang Gung University, Taoyuan, Taiwan.

Background: Previous studies have reported the occurrence of psoriasis together with multiple sclerosis (MS). Although similar predisposing genes and pathomechanisms have been hypothesized, the relationship between the two remains obscure.

Objective: The aim of this systematic review and meta-analysis was to investigate the association between psoriasis and MS. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40257-018-0399-9
Publisher Site
http://dx.doi.org/10.1007/s40257-018-0399-9DOI Listing
April 2019
22 Reads